Plasma Cell Priming
浆细胞启动
基本信息
- 批准号:9403332
- 负责人:
- 金额:$ 24.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesApoptoticAutoantibodiesAutoimmune DiseasesAutoimmunityAutomobile DrivingB cell differentiationB-LymphocytesBCL1 OncogeneBacteriaBiochemicalBiochemical PathwayBiological MarkersBloodCell CountCell divisionCellsCouplesCuesDataEnsureEvaluationEventFRAP1 geneFamilyGene DeletionGene ExpressionGene Expression ProfileGene Expression RegulationGenerationsGenesGoalsHost DefenseImmunityIn SituKineticsKnowledgeLupusMediatingMitosisMolecularPathogenicityPhasePhosphotransferasesPlasma CellsPlayPopulationPositioning AttributeProcessProteinsReceptor SignalingRestRoleSignal PathwaySignal TransductionSinusSpleenTSC1 geneTestingTherapeuticTranscriptTransgenesTranslatingTranslationsUp-RegulationWorkXBP1 geneadenoviral-mediatedcombatcytokinedifferentiated B cellexperimental studyextracellularin vitro Modelin vivoinsightmTOR inhibitionnovel strategiesplasma cell differentiationprogramsreceptorreceptor expressionresponsetranscription factortranscriptome sequencing
项目摘要
Project summary
The cellular and molecular events underlying the generation of self-reactive antibodies in
autoimmunity remain poorly understood. Notably, marginal zone (MZ) B cells are
enriched for self-reactive B cells, and are known to generate antibody-secreting plasma
cells exceptionally quickly compared to other B cells. This R21 project centers on
understanding the molecular mechanisms through which MZ B cells generate plasma
cells with accelerated kinetics, with a focus on defining extracellular cues and associated
intracellular signaling pathways that prime MZ B cells for differentiation. The central
hypothesis guiding this work is that the mTOR/mTORC1 kinase, an emerging biomarker
in lupus and related autoimmune diseases, couples BAFF-receptor signaling and
expression of relevant plasma cell genes to facilitate rapid induction of antibody
synthesis. To test this hypothesis we will: 1) Define the role of mTOR/mTORC1 signaling
in plasma cell priming, and 2) Explore the identity of extracellular inputs driving plasma
cell priming in situ. These studies will enhance knowledge of the processes underlying
the generation of all plasma cells including those secreting pathogenic self-reactive
antibodies.
项目概要
自身反应性抗体产生的细胞和分子事件
自身免疫仍然知之甚少。值得注意的是,边缘区 (MZ) B 细胞
富含自身反应性 B 细胞,已知可产生抗体分泌血浆
与其他 B 细胞相比,细胞的生长速度异常快。这个 R21 项目的重点是
了解 MZ B 细胞产生血浆的分子机制
具有加速动力学的细胞,重点是定义细胞外线索和相关的
启动 MZ B 细胞分化的细胞内信号通路。中央
指导这项工作的假设是 mTOR/mTORC1 激酶,一种新兴的生物标志物
在狼疮和相关自身免疫性疾病中,BAFF 受体信号传导与
相关浆细胞基因的表达以促进抗体的快速诱导
合成。为了检验这一假设,我们将: 1) 定义 mTOR/mTORC1 信号传导的作用
浆细胞启动,以及 2) 探索驱动血浆的细胞外输入的身份
细胞原位引发。这些研究将增强对潜在过程的了解
所有浆细胞的产生,包括那些分泌致病性自身反应的浆细胞
抗体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M Allman其他文献
David M Allman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M Allman', 18)}}的其他基金
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
- 批准号:
10637251 - 财政年份:2023
- 资助金额:
$ 24.15万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10215534 - 财政年份:2020
- 资助金额:
$ 24.15万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10443660 - 财政年份:2020
- 资助金额:
$ 24.15万 - 项目类别:
Proteasome targeting for alloreactive plasma cells
针对同种异体反应性浆细胞的蛋白酶体
- 批准号:
10652461 - 财政年份:2020
- 资助金额:
$ 24.15万 - 项目类别:
Epigenetic Control of Plasma Cell Differentiation
浆细胞分化的表观遗传控制
- 批准号:
9105812 - 财政年份:2015
- 资助金额:
$ 24.15万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 24.15万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 24.15万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 24.15万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 24.15万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 24.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 24.15万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 24.15万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 24.15万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 24.15万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 24.15万 - 项目类别:














{{item.name}}会员




